Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer
MOH_2019-05-16_007127Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Talzenna + enzalutamide with Placebo + enzalutamide (2 arms). Primary endpoint: Radiographic progression-free survival. Started Mar 2019; status: active, not recruiting.
02
Drugs
talazoparibenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2019-05-16_007127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-16_007127.